Events & Presentations

Presentations
DateTitle
January 3, 2018
Download Documentation Corporate Presentation
Get help downloading or viewing the above file types
Upcoming Events
Ovid Therapeutics Inc at RBC Capital Markets 2018 Healthcare Conference
Thursday, February 22, 2018 3:05 p.m. ET
Add to Calendar Add Ovid Therapeutics Inc at RBC Capital Markets 2018 Healthcare Conference to Calendar  Help
remind me days before the event
Enter your e-mail address 
Past Events
Ovid Therapeutics at Citi 2017 Global Healthcare Conference
Wednesday, December 6, 2017
Ovid Therapeutics at Oppenheimer Rare Disease Day
Tuesday, December 5, 2017
Ovid Therapeutics at American Epilepsy Society (AES) 71st Annual Meeting
Friday, December 1, 2017 through Tuesday, December 5, 2017
Description:

Details of the poster presentation are listed below.

Title: Clinical Trial Simulations Using a Pharmacokinetic/Enzyme Occupancy/Pharmacodynamic Model of TAK-935, a Cholesterol 24S-hydroxylase Inhibitor
Abstract ID: 344434
Session: Poster Session 1
Date and Time: Saturday, December 2, 2017, 12:00 p.m. – 2:00 p.m. ET
Location: Concourse Level, Hall B

Title: Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of TAK-935 in Healthy Subjects
Abstract ID: 344521
Session: Poster Session 2
Date and Time: Sunday, December 3, 2017, 12:00 p.m. – 2:00 p.m. ET
Location: Concourse Level, Hall B

Title: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of TAK-935 in Healthy Subjects
Abstract ID: 344533
Session: Poster Session 2
Date and Time: Sunday, December 3, 2017, 12:00 p.m. – 2:00 p.m. ET
Location: Concourse Level, Hall B

Title: Evaluation of pharmacodynamic effects of cholesterol 24-hydroxylase inhibitor TAK-935 and its target engagement in animals
Abstract ID: 344659
Session: Poster Session 2
Date and Time: Sunday, December 3, 2017, 12:00 p.m. – 2:00 p.m. ET
Location: Concourse Level, Hall B

Title: Inhibition of cholesterol 24-hydroxylase is a novel pharmacological strategy for epilepsy treatment
Abstract ID: 344660
Session: Poster Session 2
Date and Time: Sunday, December 3, 2017, 12:00 p.m. – 2:00 p.m. ET
Location: Concourse Level, Hall B

Ovid Therapeutics at Evercore ISI 2017 BioPharma Catalyst/Deep Dive Conference
Thursday, November 30, 2017 12:50 p.m. ET
Ovid Therapeutics at 29th Annual Piper Jaffray Healthcare Conference
Wednesday, November 29, 2017 9:30 a.m. ET
Ovid Therapeutics at Stifel 2017 Healthcare Conference
Tuesday, November 14, 2017 8:00 a.m. ET
Ovid Therapeutics at 18th International Fragile X and Related Neurodevelopmental Disorders Workshop
Sunday, October 15, 2017 5:00 p.m. ET
Ovid Therapeutics at Citi 12th Annual Biotech Conference
Thursday, September 7, 2017
Dr. Yaron Werber, Chief Business & Financial Officer to Participate in the JMP Securities 2017 Life Sciences Conference
Tuesday, June 20, 2017 1:00 p.m. ET
Description: The Emerging Landscape of Orphan/CNS Disorders
Location: St. Regis Hotel
2 East 55th Street
New York, NY 10022
Dr. Matthew During, Founder, President and Chief Scientific Officer to present at the Antiepileptic Drug and Device Trials XIV Conference
Friday, May 19, 2017
Description: OV935/TAK935, a novel NMDA modulator under development for epileptic encephalopathies
Location: Turnberry Isle Miami Hotel
1999 W Country Club Drive
Aventura, FL
Ovid Therapeutics to Ring The Nasdaq Stock Market Closing Bell
Wednesday, May 10, 2017 4:00 p.m. ET
Location: Nasdaq MarketSite
4 Times Square
New York, NY